• A
  • ABL1
    BCR-ABL1 Fusion, BCR-ABL1 Fusion and T315I, NUP214-ABL1 fusion, G250H, Q252H, Y253H, E255K, E255V, V299L, T315A, T315I, F317C, F317I, F317L, F317V, A337V, F359C, F359I, F359V, E459K, P465S, F486S
  • AKT1
    Oncogenic mutations, E17K, L52R, Q79K
  • AKT2
    Oncogenic mutations, E17K
  • AKT3
    Oncogenic mutations, E17K, L51R, Q78K
  • ALK
    EML4-ALK Fusion, Fusion, Fusion AND Amplification, Fusions, NPM-ALK fusion, RANBP2-ALK Fusion, SPECC1L-ALK fusion, STRN-ALK fusion, VKORC1L1-ALK fusion, Oncogenic mutations, Amplification, A348D, F856S, L1122V, G1128A, E1129V, I1151ins, T1151, T1151K, T1151M, T1151_L1152insT, L1152P, L1152R, C1156T, C1156Y, C1156Y and G1202R, D1160H, I1171, I1171N, I1171S, I1171T, I1171ins, F1174, F1174C, F1174L, F1174S, F1174V, V1180L, R1192P, L1196M, L1196M and G1202R, L1196M and L1198F, L1198F, L1198F and C1156Y, L1198F and G1202R, L1198P, G1202R, G1202R and G1269A, G1202R and L1198F, G1202del, D1203N, D1203N and E1210K, S1206C, S1206R, S1206Y, E1210K, E1210K and D1203N, E1210K and S1206C, F1245C, F1245L, F1245V, F1245Y, G1269A, G1269S, S1269S, R1275Q, D1276_R1279, Y1278S, E1408V, Protein expression
  • APC
    Oncogenic mutations, Loss-of-function mutations
  • AR
    Amplification, L702H, V716M, V731M, W742C, W742L, H875Q, H875Q and T919S, H875Y, H875Y and T878A, F877L, F877L and T878A, T878A, T878A and D891H, T878A and S889G, T878S, D880E, L882I, S889G, D891H, E894K, M896T, M896V, E898G, T919S, AR-V7, Alteration, Overexpression, Protein expression
  • AR+ESR1 (ER)
    AR:Protein expression and ESR1:Protein expression
  • ARAF
    Oncogenic mutations, S214C, P216A, K336M, K336M and G387D, R362H and G387D, G377R, G387D, G387R, G387S, P462L, Overexpression
  • ARID1A
    Oncogenic mutations, Oncogenic mutations AND Loss of protein expression, Oncogenic mutations AND NOT Loss of protein expression, Loss-of-function mutations, Truncating mutations
  • ARID1B
    Oncogenic mutations
  • ARID2
    Loss-of-function mutations
  • ATM
    Oncogenic mutations, Oncogenic mutations (germline), Loss of protein expression, Loss-of-function mutations, Loss-of-protein expression, Protein expression, Truncating mutations
  • ATM+TP53
    ATM:Oncogenic mutations and NOT TP53:Oncogenic mutations
  • ATR
    Oncogenic mutations, Overexpression
  • ATRX
    Loss-of-function mutations
  • AURKA
    Amplification
  • B
  • BAP1
    Oncogenic mutations, deletion, Loss-of-function mutations
  • BARD1
    Oncogenic mutations, Loss-of-function mutations
  • BCL2
    Amplification, G101V, D103Y, A113G, Overexpression
  • BCL2L1
    Amplification
  • BCL2L11
    deletion
  • BCL6
    Protein expression
  • BRAF
    AKAP9-BRAF fusion, Fusion, Fusions, LUC7L2-BRAF fusion, MBNL2-BRAF fusion, SND1-BRAF fusion, Class I mutations, Class II mutations, Class III mutations, Oncogenic mutations, Oncogenic mutations AND NOT V600, V600E and Amplification, V226M, F247L, D287, D287H, I326V, E375D, A400V, V459, V459L, G464E, G464V, G466, G466A, G466E, G466V, S467, S467L, G469A, G469R, G469V, L485F, L485_P490del, N486_P490del, N486_T491del, L505H, Y519F, Q524L, L525R, R558Q, G569R, N581, N581I, N581S, N581T, N581Y, D594, D594A, D594G, D594H, D594N, F595, F595L, G596, G596D, G596R, L597, L597Q, L597R, L597V, T599_V600TinsT, T599_V600insT, V600, V600E, V600E and L514V, V600K, V600M, K601, K601E, K601N, K601T
  • BRAF+EGFR
    EGFR:Oncogenic mutations and BRAF:fusion
  • BRAF+KRAS
    BRAF:V600E AND KRAS:Q61R
  • BRAF+MAP2K1
    BRAF:V600E AND MAP2K1:K57N
  • BRAF+MET
    Amplification
  • BRAF+NRAS
    BRAF:V600E AND NRAS:Q61R
  • BRAF+PTEN
    BRAF:V600E AND PTEN:Oncogenic mutations
  • BRCA1
    Oncogenic mutations, Oncogenic mutations (germline), M1I, M1V, C61G, C64Y, R71G, R71K, S1253fs*10, R1495M, E1559K, D1692H, D1692N, R1699W, A1708E, G1788V, 9435_9436delGT, Loss-of-function mutations, Promoter methylation, Reversion mutations
  • BRCA1+BRCA2
    NOT BRCA1:Oncogenic mutations (germline) and NOT BRCA2:Oncogenic mutations (germline)
  • BRCA2
    Oncogenic mutations, Oncogenic mutations (germline), M1I, M1R, V159M, V211I, V211L, R2336H, R2336P, Loss-of-function mutations, Reversion mutations
  • BRD2
    Oncogenic mutations
  • BRD3
    BRD3-NUTM1 fusion, Oncogenic mutations
  • BRD4
    BRD4-NUTM1 fusion, Fusion, Oncogenic mutations
  • BRD7
    Loss-of-function mutations
  • BRDT
    Oncogenic mutations
  • BRIP1
    Oncogenic mutations, Loss-of-function mutations
  • C
  • CALB1
    High mRNA expression
  • CAMTA1
    TAZ-CAMTA1 fusion
  • CCND1
    Amplification
  • CCND2
    Amplification
  • CCND3
    Amplification
  • CCNE1
    Amplification, Overexpression, mRNA expression
  • CCR4
    Protein expression
  • CD123
    Overexpression
  • CD19
    Overexpression, Protein expression
  • CD20
    Protein expression
  • CD274 (PD-L1)
    Amplification, Loss of protein expression, Protein expression
  • CD274+EGFR+ALK
    CD274:Protein expression and NOT EGFR:Oncogenic mutations and NOT ALK:fusion
  • CD276
    Protein expression
  • CD30
    Protein expression
  • CD33
    Protein expression
  • CD38
    Overexpression
  • CD79B
    Protein expression
  • CDH1
    Loss-of-function mutations
  • CDH6
    Protein expression
  • CDK12
    Oncogenic mutations, Loss of protein expression, Loss-of-function mutations, Protein expression, Rearrangement
  • CDK4
    Oncogenic mutations, Amplification, Amplification and NOT overexpression, Overexpression
  • CDK6
    Oncogenic mutations, Amplification, Overexpression
  • CDKN2A
    Oncogenic mutations, deletion, deletions, Loss of protein expression, Loss-of-function mutations, Truncating mutations
  • CDKN2A+MTAP
    CDKN2A:deletion and MTAP:deletion
  • CEACAM5
    Overexpression, Protein expression
  • CHEK1
    Oncogenic mutations, Loss-of-function mutations, Overexpression
  • CHEK2
    Oncogenic mutations
  • CLDN18
    Protein expression
  • CSF1
    Fusion, Overexpression, Rearrangement
  • CSF1R
    Oncogenic mutations, Overexpression
  • CTNNB1
    T41A, S45F, Gain-of-function mutations
  • CXCL13
    Overexpression
  • Chromosome
    3p25.3 copy number gain
  • Consensus molecular subtype
    CMS2, CMS3, CMS4
  • D
  • DAXX
    Overexpression
  • E
  • EGFR
    EGFR-PURB fusion, EGFR-RAD51 fusion, EGFR-SEPT14 Fusion, KIF5B-EGFR fusion, Amplification AND NOT Oncogenic mutations, Amplification and NOT Oncogenic mutation, Oncogenic mutations, Exon 18 deletion, Exon 18 mutation, Amplification and Exon 19 deletion, Exon 19 deletion, Exon 19 deletion and C797S, Exon 19 deletion and G724S, Exon 19 deletion and G796S, Exon 19 deletion and L718Q, Exon 19 deletion and L718V, Exon 19 deletion and L792F, Exon 19 deletion and L792H, Exon 19 deletion and T790M, Exon 19 deletion and T790M and C797S, Exon 19 deletion and T790M and G724S, Exon 19 deletion and T790M and L718V, Exon 19 deletion and T790M and L792H, Exon 19 deletion and T854I, Exon 19 deletion and amplification, Exon 19 deletions, Exon 19 indels, Exon 19 insertion, Exon 20 insertion, Exon 20 insertion and T790M and C797S, Exon 20 insertion except A763_Y764insFQEA, Exon 20 insertions, Exon 20 mutation, Exon 21 mutation, Exon 21 mutation and amplification, Amplification, Amplification AND G598V, Amplification and L858R, L858R and amplification, T263P, A289D, A289V, R451C, S464L, G465R, K467T, I491M, S492R, G598V, E709A, E709A and G719S, E709K, E709K and G719S, E709K and L858R, E709_T710delinsD, L718Q, L718Q and T790M, L718V, G719, G719A, G719A and L861Q, G719A and R776C, G719A and T790M, G719S, G719S and E709K, G719S and R776H, G719S and T790M, G719Y, S720P, G724S, G724S and R776H, G724S and T790M, T725M, I740_K745dupIPVAIK, I740dupIPVAK, L747P, L747S, L747_A750delinsP, L747_K754delInsATSPE, L747_P753delinsS, L747_T751del and D837T, T751_I759delinsS, S752_I759del, K754E, K757R, D761N, D761Y, A763_Y764insFQEA, A763_Y764insLQEA, A763insFQEA, A767_V769dup, A767insASV, S768I, S768I and T790M, S768I and V769L, S768I and V774M, S768_D770dup, S768dupSVD, S768dupSVD and V769M, V769L, V769_D770insASV, V769_D770insGG, V769insASV, D770_N771insG, D770_N771insGD, D770_N771insGL, D770_N771insSVD, D770delinsDV, D770delinsGY, D770insG, D770insNPG, D770insSVD, D770insY, N771_P772insH, N771_P772insSVDN, N771delinsKH, N771dupN, N771dupN and G724S, N771insH, P772_H773insPNP, P772dupDNP, H773Y, H773_V774insAH, H773_V774insH, H773_V774insNPH, H773_V774insPHPH, H773insH, H773insNPH, V774M, V774_C775insHV, R776C, R776H, F784F, S784F, T790M, T790M and C797S and T790M-C797S trans-allelic conformation, T790M and G796R, T790M and L792H, L792H, C797G, C797S, K806E, S811F, N826Y, L833F, L833V, L833V and H835L, N842S, V843I, T847I, V851I, T854A, L858R, L858R and A871E, L858R and C797G, L858R and C797S, L858R and G724S, L858R and G873E, L858R and L718Q, L858R and L718V, L858R and L792F, L858R and L792H, L858R and S784F, L858R and T790M, L858R and T790M and C797S, L858R and T790M and L718Q, L858R and T790M and L718V, L858R and T790M and L792H, L858R and T790M and V843I, L858R and V834L, L861Q, L861R, Kinase domain duplication, Kinase domain duplication AND T790M, Kinase domain duplication AND T790M AND C797S, Overexpression, Protein expression, ectodomain mutation, vIII, vIII AND D247Y
  • EGFR+ALK
    EGFR:Oncogenic mutations and ALK:fusion
  • EGFR+BRAF
    EGFR:Oncogenic mutations and BRAF:V600E
  • EGFR+EGFR
    Amplification and Exon 19 deletion, C797S and Exon 19 deletion, E709K and Exon 19 deletion, G724S and Exon 19 deletion, G796S and Exon 19 deletion, L718 and Exon 19 deletion, L792H and Exon 19 deletion, Amplification and L858R, E709K and L858R, L718 and L858R, G724S and L858R, L792H and L858R, G796S and L858R, C797S and L858R, EGFR:T790M and EGFR:C797S and EGFR:T790M-C797S cis-allelic conformation
  • EGFR+ERBB2 (HER2)
    EGFR:Oncogenic mutations and ERBB2:amplification
  • EGFR+ERRFI1
    EGFR:low expression AND ERRFI1:Oncogenic mutations, EGFR:overexpression AND ERRFI1:Oncogenic mutations
  • EGFR+MET
    EGFR:Oncogenic mutations and MET:amplification, EGFR:Oncogenic mutations and MET:amplification and NOT EGFR:T790M, MET:Alteration and EGFR:Oncogenic mutations, EGFR:L858R and MET:exon 14 skipping mutation, EGFR:Exon 19 deletion and MET:amplification, EGFR:Exon 19 deletion and MET:exon 14 skipping mutation, MET:amplification and EGFR:exon 19 deletion, EGFR:L858R and MET:amplification, EGFR:T790M and MET:amplification, MET:amplification and EGFR:L858R
  • EGFR+RB1
    EGFR:Oncogenic mutations and RB1:Oncogenic mutations
  • EGFR+RET
    EGFR:Oncogenic mutations and RET:fusion
  • EGFR+ROS1
    EGFR:Oncogenic mutations and ROS1:fusion
  • EGFR+TP53
    EGFR:Oncogenic mutations and TP53:Oncogenic mutations
  • EIF1AX
    G6_splice, G8V, G9, K10N, R13, G15D, A113_splice, N-terminal tail mutation
  • EIF1AX+NRAS
    EIF1AX:A113splice and NRAS:Oncogenic mutations, EIF1AX:Oncogenic mutations and NRAS:Oncogenic mutations
  • EMSY
    Amplification, Overexpression
  • EPAS1
    Oncogenic mutations (germline), A530E (germline)
  • EPHA7
    Oncogenic mutations
  • ERBB2 (HER2)
    MDK-ERBB2 fusion, ZNF207-ERBB2 fusion, ERBB2:Oncogenic mutations and NOT ERBB2:amplification, Oncogenic mutations, Exon 16 skipping mutation, Exon 20 insertion, Exon 20 insertion except G778ins, Exon 20 mutation, Exon 21 mutation, Amplification, Amplification and S310F, ERBB2:amplification, ERBB2:amplification and KRAS:G12D, Low protein expression and NOT Amplification, Protein expression AND Amplification, Protein expression and NOT Amplification, Q57R, S250C, E265K, D277H and S310F, G309A, S310, S310F, S310Y, S335C, E395K, L403V, R487W, S653C, V659D, V659E, G660D, G660D and S310F, G660R, Q678Q, R678Q, D679H, V697L, Q709, D742N, K753E, L755F, L755M, L755P, L755S, L755_759del, G766V, I767M, I767N, A769H, D769H, D769Y, A775_G776insTVMA, A775_G776insYVMA, A775_Y776insYVMA, G776, G776C, G776R, G776S, G776V, G776delinsLC, G776delinsVC, G776delinsVG, G776ins, V777L, V777_G778insV, G778_P780dup, G778_S779insG, G778_S779insLPS, G778ins, G778insCPG, S779_P780insVGS, S779ins, P780_Y781insGSP, P780ins, L785F, L786V, T798I, C805S, G815R, L841V, V842I, N857S, T862A, L869R, R896C, D962N, P1199T, Alteration, Extracellular domain mutations, Juxtamembrane domain mutation, Kinase domain mutation, Low protein expression, No protein expression, Overexpression, Protein expression, Transmembrane domain mutation, transmembrane domain mutations
  • ERBB2 (HER2)+ESR1 (ER)
    ESR1:Protein expression and NOT ERBB2:amplification and NOT ERBB2:overexpression
  • ERBB2 (HER2)+KRAS
    ERBB2:Amplification AND KRAS:Oncogenic mutations, ERBB2:Amplification and ERBB2:Protein expression and NOT KRAS:Oncogenic mutations and NOT BRAF:V600E, ERBB2:Oncogenic mutations AND KRAS:Oncogenic mutations, ERBB2:Overexpression AND KRAS:Oncogenic mutations, ERBB2:Overexpression and NOT KRAS:Oncogenic mutations and NOT BRAF:V600E, ERBB2:amplification and KRAS:G12, ERBB2:amplification and KRAS:G12D
  • ERBB3
    Oncogenic mutations, Amplification, F94L, R103G, V104L, V104M, G248R, P262H, G284R, D297Y, T355A, T355I, Q809R, E928G, E1261A, Overexpression, Protein expression
  • ERBB4
    Oncogenic mutations
  • ERCC1
    Oncogenic mutations, Loss of protein expression
  • ERCC2
    Oncogenic mutations
  • ERRFI1
    deletion, E384X, Loss-of-function mutations
  • ESR1 (ER)
    Oncogenic mutations, E380, E380Q, V392I, F404I, F404L, F404V, S463P, V534E, P535H, L536, L536H, L536P, L536Q, L536R, Y537, Y537C, Y537N, Y537S, D538, D538G, Protein expression
  • ESR1 (ER)+ERBB2 (HER2)
    ESR1:Protein expression and NOT ERBB2:amplification and NOT ERBB2:overexpression, NOT ESR1:protein expression and NOT ERBB2:amplified
  • ESR1 (ER)+PIK3CA
    ESR1:protein expression and PIK3CA:oncogenic mutation
  • EZH2
    Oncogenic mutations, Y641C, Y641F, Y641H, Y641N, Y641S, Y646, Y646C, Y646F, Y646H, Y646N, Y646S, A677G, A682G, A687V, A692V
  • F
  • FAM175A
    Loss-of-function mutations
  • FANCA
    S1088F, Loss-of-function mutations
  • FANCC
    Oncogenic mutations, Loss of protein expression
  • FANCD2
    Oncogenic mutations, Oncogenic mutations (germline), Loss-of-function mutations
  • FANCG
    Oncogenic mutations
  • FANCI
    Oncogenic mutations
  • FANCL
    Oncogenic mutations
  • FANCM
    Oncogenic mutations, S1045, Loss-of-function mutations
  • FAT1
    Loss-of-function mutations
  • FBXW7
    Oncogenic mutations, deletion, L403fs*34, R465C, R479Q, R505, R505C, R505H, G579W, R658Q, S668fs*39, Loss-of-function mutations
  • FGF19
    Amplification, Overexpression
  • FGFR1
    FGFR1-PLAG1 fusion, FGFR1-TACC1 fusion, Fusion, Oncogenic mutations, Oncogenic mutations and NOT V561, Amplification, N546D, N546K, V561M, M563T, N564K, Alteration, Overexpression
  • FGFR2
    FGFR1-WDHD1 fusion, FGFR2-ACLY fusion, FGFR2-AFF4 fusion, FGFR2-AHCYL1 fusion, FGFR2-ARHGAP22 fusion, FGFR2-ARHGAP24 fusion, FGFR2-ATAD2 fusion, FGFR2-ATF2 fusion, FGFR2-BICC1 fusion, FGFR2-BICD1 fusion, FGFR2-CASP7 fusion, FGFR2-CCDC158 fusion, FGFR2-CCDC170 fusion, FGFR2-CCDC6 fusion, FGFR2-CEP128 fusion, FGFR2-CLIP1 fusion, FGFR2-COL16A1 fusion, FGFR2-CTNNA3 fusion, FGFR2-DBP fusion, FGFR2-DNAJC12 fusion, FGFR2-EEA1 fusion, FGFR2-EIF4ENIF1 fusion, FGFR2-FILIP1 fusion, FGFR2-GAB2 fusion, FGFR2-GOPC fusion, FGFR2-INSC fusion, FGFR2-KCTD1 fusion, FGFR2-KIAA1217 fusion, FGFR2-KIAA1598 fusion, FGFR2-LAMC1 fusion, FGFR2-MACF1 fusion, FGFR2-MATR3 fusion, FGFR2-MCU fusion, FGFR2-NEDD4L fusion, FGFR2-NOL4 fusion, FGFR2-NRAP fusion, FGFR2-NRBF2 fusion, FGFR2-PAH fusion, FGFR2-PAWR fusion, FGFR2-POC1B fusion, FGFR2-PXN fusion, FGFR2-RABGAP1L fusion, FGFR2-RASSF4 fusion, FGFR2-RPAP3 fusion, FGFR2-SFI1 fusion, FGFR2-SHROOM3 fusion, FGFR2-SLMAP fusion, FGFR2-SOGA1 fusion, FGFR2-SPICE1 fusion, FGFR2-STRN4 fusion, FGFR2-TACC1 fusion, FGFR2-TFEC fusion, FGFR2-TRIM8 fusion, FGFR2-TTC28 fusion, FGFR2-TXLNB fusion, FGFR2-USH2A fusion, FGFR2-VCL fusion, FGFR2-WAC fusion, FGFR2-WDHD1 fusion, FGFR2-ZMYM4 fusion, FTFR2-TRIM8 fusion, Fusion, Fusions, Oncogenic mutations, Oncogenic mutations and NOT Amplification, Oncogenic mutations and NOT V564, Amplification, S252W, W290C, C382R, C383R, C492, N549H, N549K, N550, N550H, N550K, V564F, V564I, V564M, E565A, V565, V565I, V565L, E566G, L617M, L617V, K641R, K659M, K659N, K660M, FGFR2 rearrangement, FGFR2-USP33, Overexpression
  • FGFR3
    FGFR3-BAIAP2L1 fusion, FGFR3-TACC3 fusion, Fusion, Fusions, Oncogenic mutations, Oncogenic mutations and NOT V565 and NOT V550, Amplification, R248C, S249C, G370C, Y373C, Y375C, F386L, A393E, V443, V555M, K650E, Alteration, Overexpression
  • FGFR4
    V550E, V550L
  • FH
    Oncogenic mutations, Loss-of-function mutations (germline)
  • FLI1
    EWSR1-FLI1 Fusion
  • FLT3
    Oncogenic mutations, D835, I836, Internal tandem duplication, Kinase domain mutation
  • FOLR1
    Overexpression, Protein expression
  • FRS2
    Amplification
  • G
  • GLI1
    Overexpression
  • GLI2
    Overexpression
  • GNA11
    Oncogenic mutations
  • GNAQ
    Oncogenic mutations
  • I
  • IDH1
    Oncogenic mutations, R132, R132C, R132G, R132H, R132L, R132S, S280F
  • IDH2
    Oncogenic mutations, R140, R140Q, R172, R172K, R172S, V305M
  • IRS2
    Amplification, Protein expression
  • IRS2+BRAF
    IRS2:Amplification AND BRAF:V600E
  • IRS2+KRAS
    IRS2:Amplification AND KRAS:G13D
  • Immunoscore IC
    High
  • Intrinsic subtype
    Basal-like, HER2-enriched, Luminal A, Luminal B, Normal-like
  • J
  • JAK1
    F958C, F958V, P960
  • JAK2
    PCM1-JAK2 fusion, V617F, Y931C, Y931C and V617F
  • K
  • KDM6A
    Oncogenic mutations, Loss-of-function mutations
  • KEAP1
    Oncogenic mutations
  • KEAP1+KRAS
    KRAS:G12C AND NOT KEAP1:Oncogenic mutations
  • KIT (CD117)
    Oncogenic mutation, Oncogenic mutations, Oncogenic mutations and NOT Amplification, Oncogenic mutations and NOT Amplification and NOT Exon 17 mutation, Exon 9 mutation, Exon 9 mutations, Exon 11 deletion, Exon 11 mutation, Exon 11 mutations, Exon 13 mutation, Exon 17 mutation, Exon 17 mutations, Amplification, A502_Y503dup, Y553N, D557, K558_G565delinsR, V559A, V559C, V559D, V559G, V560D, V560G, V560_Y578del, V560del, L576P, P577_Y579del, K624E, K642E, V654A, N655S, V669D, T670A, T670I, T670V, N680K, F681L, R796G, C809G, D816, D816E, D816F, D816G, D816H, D816I, D816V, D816Y, I817L, D820A, D820E, D820G, D820N, D820V, D820Y, N822H, N822I, N822K, N822T, N822Y, Y823D, A829P, S840N, Overexpression, Protein expression
  • KMT2C
    deletion, Loss-of-function mutations
  • KRAS
    NOT KRAS:oncogenic mutation, NOT oncogenic mutations, Oncogenic mutations, Exon 3 insertion, Amplification, Amplification and NOT missense variant, G12C AND Amplification, V8L, V9F, G12, G12A, G12C, G12D, G12R, G12S, G12V, G12W, G13C, G13D, V14L, K16T, A59S, G60_A66dup, Q61H, Q61K, Q61R, E62D, E62_A66dup, Y64N, R68S, M72L, G77V, H95D, H95Q, H95R, Y96C, Y96D, Q99K, K117N, D119H, A146P, A146V, R149C, Switch 2 duplication
  • KRAS+ERBB3
    KRAS:Oncogenic mutations and ERBB3:Overexpression
  • KRAS+MET
    MET:exon 14 skipping mutation and KRAS:Oncogenic mutations
  • KRAS+Microsatellite Instability
    KRAS:Oncogenic mutations AND Microsatellite Instability:High
  • KRAS+Mismatch repair
    KRAS:Oncogenic mutations AND Mismatch repair:deficient
  • KRAS+NRAS
    NOT KRAS:exon 2 mutation and NOT KRAS:exon 3 mutation and NOT KRAS:exon 4 mutation and NOT NRAS:exon 2 mutation and NOT NRAS:exon 3 mutation and NOT NRAS:exon 4 mutation
  • KRAS+STK11
    KRAS:G12C and STK11:Oncogenic mutations
  • M
  • MAP2K1
    Oncogenic mutations, F53L, Q56P, K57N, K57T, K57_G61del, L98_K104delinsQ, I99_K104del, E102_I103del, P105_107del, C121S, P124L, P124Q, P142L
  • MAP2K1+BRAF
    MAP2K1:P124 and BRAF:V600
  • MAP2K2
    Oncogenic mutations, V35M, L46F, Q60P, C125S, N126D, Y134H
  • MAP2K4
    Oncogenic mutations
  • MAP3K1
    Oncogenic mutations
  • MAPK1 (ERK2)
    Y36H, Y36N, P58L, P58S, P58T, Y64N, C65Y, Y131F, A189V, S202P, D321G, E322K
  • MAPK3 (ERK1)
    Y53H, G54A, S74G, P75L, Y81C, C82Y, R84H, Q90R, Y148H, G186D, A206V, S219P
  • MCL1
    Amplification
  • MDM2
    Amplification, Overexpression
  • MDM2+TP53
    MDM2:Amplification AND NOT TP53:Oncogenic mutations
  • MET
    Fusions, Oncogenic mutations, Exon 14 Deletion, Exon 14 skipping mutation, Exon 14 splicing mutation, Amplification, S244fs, N375S, Y1003 (Y1021), Y1003S (Y1021S), F1007fs (F1025fs), D1010 (D1028), Y1021H (Y1003H), D1028H (D1010H), D1028N (D1010N), H1094Y (H1112Y), G1163, G1163 (G1181), G1163R (G1181R), L1195V (L1213V), F1200I (F1218I), D1228, D1228 (D1246), D1228A (D1246A), D1228H (D1246H), D1228H (D1246N), D1228N (D1246N), Y1230 (Y1248), Y1230C (Y1248C), Y1230H (Y1248A), Y1230H (Y1248H), Y1230S (Y1248S), D1246 (D1228), D1246N (D1228N), Y1248 (Y1230), Y1248H (Y1230H), K1262R (K1244R), Alteration, Alterations, No protein expression, Overexpression, c.2888-5_2944del
  • MET+KRAS
    MET:Amplification and KRAS:G12V
  • MET+TP53
    MET:Exon 14 skipping mutation and TP53:Oncogenic mutations
  • MET1
    CAV-MET1 fusion
  • MGMT
    Loss of protein expression, Loss-of-function mutations, Low protein expression, Methylation, Promoter methylation
  • MLH1
    Loss of protein expression, Loss-of-function mutations, Promoter methylation
  • MRAS
    Q71R
  • MRE11A
    Oncogenic mutations (germline), L169Rfs*14, Loss-of-function mutations
  • MSH2
    R359S (germline), Loss of protein expression, Loss-of-function mutations, Promoter methylation
  • MSH6
    Loss-of-function mutations, Promoter methylation
  • MSLN
    Overexpression, Protein expression
  • MTAP
    deletion
  • MTOR
    Oncogenic mutations, L1460P, E2014K, F2108L, L2209V, Q2223K, E2419K, L2427Q
  • MTORC1
    Oncogenic mutations
  • MYB
    Alteration, Overexpression
  • MYC
    Oncogenic mutations, Amplification, Overexpression
  • MYCL
    Overexpression
  • MYCN
    Oncogenic mutations, Amplification, Overexpression
  • MYD88
    Oncogenic mutations, L265P, Gain-of-function mutations
  • Microsatellite Instability (MSI)
    High, Stable
  • Microsatellite instability+Mismatch repair
    NOT Microsatellite instability:high AND NOT Mismatch repair:deficient
  • Mismatch repair (MMR)
    Deficient, High
  • Molecular subtype
    BLIA molecular subtype
  • N
  • NBN
    Oncogenic mutations
  • NECTIN4
    Protein expression
  • NF1
    Oncogenic mutations, Oncogenic mutations (germline), deletion, N184fs, Q1336*, R2637*, Loss-of-function mutations
  • NF1+KIT
    NF1:Oncogenic mutations AND NOT KIT:Oncogenic mutations
  • NF1+MET
    NF1:Oncogenic mutation AND MET:Amplification, NF1:Deletion AND MET:Amplification
  • NF1+SUZ12
    NF1:deletion AND SUZ12:deletion, NF1:Loss-of-function mutations AND SUZ12:Loss-of-function mutations
  • NF2
    Oncogenic mutations, deletion, Loss-of-function mutations, Truncating mutations
  • NOTCH1
    Oncogenic mutations, R2327fs*, Alterations, Overexpression
  • NOTCH2
    Gain-of-function mutations, Rearrangements
  • NOTCH3
    Overexpression
  • NRAS
    Oncogenic mutations, Amplification, G12, G12C, G13, G13R, Q61, Q61K, Q61R, Q61S
  • NRG1
    APP-NRG1 fusion, ATP1B1-NRG1 fusion, CD74-NRG1 fusion, CDH1-NRG1 fusion, CLU-NRG1 fusion, DOC4-NRG1 fusion, Fusion, Fusions, ITGB1-NRG1 fusion, POMK-NRG1 fusion, RBPMS-NRG1 fusion, SDC4-NRG1 fusion, SLC3A2-NRG1 fusion, VAMP2-NRG1 fusion, VTCN1-NRG1 fusion, High mRNA expression, Overexpression
  • NTRK1
    ATP1A4-NTRK1 fusion, Alterations AND NOT fusion, CD74-NTRK1 fusion, CDC42BPA-NTRK1 fusion, CGN-NTRK1 fusion, CTRC-NTRK1 fusion, DDR2-NTRK1 fusion, DIAPH1-NTRK1 fusion, EPS15-NTRK1 fusion, EPS15L1-NTRK1 fusion, ERC1-NTRK1 fusion, Fusion, Fusions, GON4L-NTRK1 fusion, IRF2BP2-NTRK1 fusion, LMNA-NTRK1 fusion, NFASC-NTRK1 fusion, PDE4DIP-NTRK1 fusion, PDIA3-NTRK1 fusion, PEAR1- NTRK1 fusion, PLEKHA6-NTRK1 fusion, PPL-NTRK1 fusion, SQSTM1-NTRK1 fusion, TPM3-NTRK1 fusion, TPR-NTRK1 fusion, TRIM33-NTRK1 fusion, TRIM63-NTRK1 fusion, Amplification, F589L, G595R, A608D, G667C, G667S, High mRNA expression
  • NTRK2
    Alterations AND NOT fusion, Fusion, Fusions, GNAQ-NTRK2 fusion, KANK1-NTRK2 fusion, RBPMS-NTRK2 fusion, SQSTM1-NTRK2 fusion, STRN-NTRK2 fusion, TRAF2-NTRK2 fusion, Q596E, Q596P, F617C, F617I, F617L, G623S, G639R, High mRNA expression
  • NTRK3
    AKAP13-NTRK3 fusion, ARNT2-NTRK3 fusion, Alterations AND NOT fusion, EML4-NTRK3 fusion, ETV6-NTRK3 fusion, FAM19A2-NTRK3 fusion, Fusion, Fusions, IQGAP1-NTRK3 fusion, KIF7-NTRK3 fusion, MYO5A-NTRK3 fusion, RBPMS-NTRK3 fusion, SPECC1L-NTRK3 fusion, SQSTM1-NTRK3 fusion, TFG-NTRK3 fusion, TPM4-NTRK3 fusion, G623E, G623R, G696A, High mRNA expression, Protein expression
  • NUTM1
    Protein expression
  • P
  • PALB2
    Oncogenic mutations, Oncogenic mutations (germline), Loss-of-function mutations, Loss-of-function mutations (germline)
  • PBRM1
    Oncogenic mutations, Loss-of-function mutations
  • PDCD1LG2
    Amplification
  • PDGFB
    COL1A1-PDGFB Fusion
  • PDGFRA
    FIP1L1-PDGFR fusion, FIP1L1-PDGFRA Fusion, FIP1L1-PDGFRA fusion and T674I, Fusion, Oncogenic mutations, Exon 18 deletion, Exon 18 mutation, Amplification, V561D, N659K, T674I, D842V, D842Y, D842_H845del, D842_I843delinsIM, I843_D846del, I843_H846del, Overexpression, Protein expression
  • PDGFRB
    Fusions
  • PGR
    Protein expression
  • PIK3CA
    Oncogenic mutations, Amplification, R88Q, G118D, N345K, N345T, C420R, E453K, E542, E542K, E542K and E453, E542K and E726K, E542K and M1043, E543Q and H1047R, E545, E545A, E545D, E545G, E545K, E545K and E453, E545K and E726, Q546, Q546E, Q546R, Q546X, E726, E726K and H1047R, M1043I, H1047, H1047L, H1047R, H1047R and E453, H1047R and E726K, H1047Y, G1049R, H1074R
  • PIK3CA+ESR1 (ER)+ERBB2 (HER2)
    PIK3CA:Oncogenic mutations and ESR1:protein expression and NOT ERBB2:amplification and NOT ERBB2:overexpression
  • PIK3CA+FGFR1
    PIK3CA:Oncogenic mutation AND FGFR1:Alteration
  • PIK3CA+FGFR2
    PIK3CA:Oncogenic mutation AND FGFR1:Alteration
  • PIK3R1
    Oncogenic mutations, S361fs
  • PMS2
    K706Sfs, Loss-of-function mutations, Promoter methylation
  • POLD1
    Oncogenic mutations, Loss of protein expression
  • POLE
    Oncogenic mutations, P286R, T323A, V411L
  • PPM1D
    Loss-of-function mutations
  • PPP2R2A
    Oncogenic mutations
  • PRKCA
    Fusion
  • PRKCB
    Fusion
  • PRKDC
    Oncogenic mutations, Loss-of-function mutations
  • PSMA
    Protein expression
  • PTCH1
    Oncogenic mutations, Loss-of-function mutations, Truncating mutations
  • PTEN
    Oncogenic mutations, N48K, G209V, Alteration, Loss of protein expression, Loss-of-function mutations
  • PTEN+ERBB2 (HER2)
    PTEN:Loss of protein expression and ERBB2:amplification
  • PTPN11
    Oncogenic mutations, E72K, E76K, P491Q, Loss-of-function mutations
  • R
  • RAC1
    P29S
  • RAD50
    Oncogenic mutations, deletions, Loss-of-function mutations
  • RAD51
    Low protein expression
  • RAD51B
    Oncogenic mutations
  • RAD51C
    Oncogenic mutations, Oncogenic mutations (germline), Loss-of-function mutations
  • RAD51D
    Oncogenic mutations
  • RAD54L
    Oncogenic mutations
  • RAF1
    ANO10-RAF1 fusion, ATG7-RAF1 fusion, FYCO1-RAF1 fusion, Fusion, Fusions, GATM-RAF1 fusion, GOLGA4-RAF1 fusion, NFIA-RAF1 fusion, QKI-RAF1 fusion, RAF1-CCDC176 fusion, RAF1-TRAK1 fusion, SRGAP3-RAF1 fusion, Oncogenic mutations, K106N, S257P, P261L, P261T, G356E, G361A, S427T, D447N, M469I, E478K, R554K
  • RASA1
    Oncogenic mutations, Loss-of-function mutations
  • RB1
    Oncogenic mutations, Heterozygous deletion, Copy number loss, Loss of protein expression, Loss-of-function mutation, Loss-of-function mutations
  • RET
    ARHGAP12-RET fusion, CCDC186-RET fusion, CCDC6-RET fusion, CCDC88C-RET fusion, CLIP1-RET fusion, DOCK1-RET fusion, ERC1-RET fusion, Fusion, Fusions, KIF5B-RET fusion, KTN1-RET fusion, NCOA4-RET fusion, PRKAR1A-RET fusion, RBPMS-RET fusion, RELCH-RET fusion, RET fusions and NOT KIF5B-RET fusion, RUFY3-RET fusion, TRIM24-RET fusion, TRIM33-RET fusion, Oncogenic mutations, Oncogenic mutations (germline), Oncogenic mutations and NOT Amplification, D378_G385delinsE, C609, C611, C618, C620, C630, D631_L633delinsE, D631_L633delinsV, E632_L633del, C634, T636_V637insCRT, K666N, V738A, I788N, L790F, G801S, V804L, V804M, Y806C, Y806N, G810A, G810C, G810R, G810S, A883F, D898_E901del, D903_S904delinsEP, S904F, M918T, Cysteine rich domain mutation
  • RICTOR
    Amplification
  • RIT1
    P128L
  • RNF43
    Oncogenic mutations, deletion, R371fs, G659fs, P660fs, C-terminal truncating mutations, Frameshift mutations, Loss-of-function mutations, Truncating mutations
  • ROS1
    CD74-ROS1 fusion, EZR-ROS1 fusion, Fusion, Fusions, GOPC-ROS1 Fusion, SLC12A2-ROS1 fusion, SLC4A4-ROS1 fusion, Amplification, E1395G, L1947R, L1951R, G1971E, S1986F, S1986Y, F2004C, L2026M, G2032R, D2033N, S2060G, F2075V, V2098U, G2101A, D2113G, L2155S
  • ROS1+MET
    ROS1:fusion AND MET:D1228N
  • RSPO1
    Fusion
  • S
  • SDHA
    Oncogenic mutations (germline)
  • SDHB
    Oncogenic mutations (germline)
  • SETD2
    Truncating mutations
  • SF3B1
    Oncogenic mutations
  • SLAMF7
    Protein expression
  • SLC1A5
    Overexpression
  • SLX4
    Loss-of-function mutations
  • SMARCA2
    Loss-of-function mutations
  • SMARCA2+SMARCA4
    SMARCA2:Loss of protein expression and SMARCA4:Loss of protein expression
  • SMARCA4
    Oncogenic mutations, Loss of protein expression, Loss-of-function mutations
  • SMARCB1
    Oncogenic mutations, deletion, Loss of protein expression
  • SMO
    Oncogenic mutations, R168H, E181K, R199Q, N219D, L221P, N223D, L225R, T241M, V281C, W281L, V321M, A327P, T336I, T349I, T349P, L353F, D384N, V386A, S387N, D388N, C390R, S391N, V404M, I408V, L412F, V414A, G453D, G457S, A459V, D473, D473G, D473H, D473Y, N476K, D477G, Q477E, E481G, G497W, D506N, P513L, E518, E518K, K519R, E522K, T534I, W535L, T548I, K564E, T640A, P641A, P698T, P739L, P739S
  • SRSF2
    P95H
  • SSTR2
    Protein expression
  • STK11
    Oncogenic mutations
  • STK11+KRAS
    STK11:Oncogenic mutations AND KRAS:Oncogenic mutations
  • SUFU
    Loss-of-function mutations
  • SUZ12
    Loss-of-function mutations
  • V
  • VHL
    Oncogenic mutations, Oncogenic mutations (germline)
  • W
  • WT1
    Loss-of-function mutations
  • X
  • XPO1
    C528S
  • XRCC2
    Loss-of-function mutations
  • Y
  • YAP1
    Fusion, YAP1-TFE3 fusion
© 2020, Garvan Institute of Medical Research & Omico Ltd.
The Kinghorn Cancer Centre, 370 Victoria Street, Darlinghurst NSW 2010, Australia.